New hope for relapsed leukemia: targeted drug combo enters human trials
NCT ID NCT06561152
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a combination of the targeted drug tagraxofusp with two chemotherapy drugs (cladribine and cytarabine) in 20 adults whose acute myeloid leukemia (AML) has come back or not responded to prior treatment. The goal is to find the safest dose and see how well the combination works at putting the cancer into remission. Participants must have a specific marker on their leukemia cells called CD123 and have already received standard initial therapy.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Stanford University
RECRUITINGPalo Alto, California, 94304, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New drug aims to wake up immune system against Hard-to-Treat leukemia
- New drug combo aims to outsmart resistant leukemia
- Gentler chemo approach shows promise for tough blood cancers in older patients
- Selective immune cell removal may tame transplant complications
- Promising combo for IDH1 leukemia hits early snag – trial stopped
- Engineered immune cells take aim at Hard-to-Treat leukemia